Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $208.00

Krystal Biotech (NASDAQ:KRYS) had its target price lifted by Chardan Capital from $153.00 to $208.00 in a report released on Monday, Benzinga reports. Chardan Capital currently has a buy rating on the stock.

A number of other analysts also recently commented on the stock. HC Wainwright restated a buy rating and set a $200.00 price target on shares of Krystal Biotech in a research report on Monday. Stifel Nicolaus reissued a buy rating and set a $204.00 target price (up previously from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $185.63.

Krystal Biotech Stock Down 1.2 %

NASDAQ KRYS traded down $2.10 on Monday, hitting $178.61. The stock had a trading volume of 363,297 shares, compared to its average volume of 381,974. The company’s 50-day moving average is $185.49 and its two-hundred day moving average is $164.19. The stock has a market cap of $5.10 billion, a price-to-earnings ratio of 94.50 and a beta of 0.84. Krystal Biotech has a one year low of $93.95 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, August 5th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.50 by $0.03. The business had revenue of $70.28 million during the quarter, compared to analyst estimates of $65.27 million. During the same quarter in the prior year, the business earned ($1.25) earnings per share. The firm’s revenue was up 70283900.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Krystal Biotech will post 2 earnings per share for the current year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total value of $4,394,000.00. Following the transaction, the insider now owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total value of $4,394,000.00. Following the completion of the sale, the insider now owns 1,525,882 shares in the company, valued at approximately $268,189,020.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Julian S. Gangolli sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $164.13, for a total transaction of $3,282,600.00. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently bought and sold shares of the business. Prime Capital Investment Advisors LLC acquired a new stake in shares of Krystal Biotech during the fourth quarter worth approximately $310,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Krystal Biotech by 7.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,484 shares of the company’s stock valued at $1,673,000 after buying an additional 969 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in shares of Krystal Biotech by 8.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 59,324 shares of the company’s stock valued at $7,360,000 after buying an additional 4,588 shares during the period. Perigon Wealth Management LLC grew its holdings in shares of Krystal Biotech by 19.4% during the 4th quarter. Perigon Wealth Management LLC now owns 4,874 shares of the company’s stock valued at $605,000 after acquiring an additional 791 shares in the last quarter. Finally, HealthInvest Partners AB acquired a new position in shares of Krystal Biotech in the fourth quarter worth $822,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).